Conduit Pharmaceuticals and Charles River Laboratories have announced a partnership to evaluate AZD1656, a glucokinase activator, in a preclinical model of systemic lupus erythematosus (SLE).

As of Tuesday, February 18, vTv Therapeutics Inc.’s VTVT share price has dipped by 10.20%, which has investors questioning if this is right time to buy.

The light-modulated protein kinase CDK5 is important for phase shifts of the circadian clock, impacting phase delays through calcium influx and signaling pathways, crucial for adapting to jet lag.